Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech company based in Chengdu, has announced that it has received approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase I/II clinical study for its drug candidate HP537 in the treatment of hematologic malignancies. The Category 1 chemical had previously been cleared for clinical trials in China in February this year.
HP537, an in-house developed small molecule anti-tumor drug, functions by binding to the p300/CBP bromine domain (BRD), thereby inhibiting the progression, growth, and differentiation of tumor cells. It blocks the p300/CBP signaling pathway, which is involved in the development of various hematologic malignancies. The drug is under development for the treatment of multiple myeloma (MM), non-Hodgkin’s lymphoma (NHL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other related conditions.- Flcube.com
